유럽의 응고 시장 예측(-2030년) : 지역별 분석 - 증상별, 유형별, 제공별, 기술별, 최종사용자별

The Europe coagulation market was valued at US$ 2,000.64 million in 2022 and is expected to reach US$ 3,379.71 million by 2030; it is estimated to grow at a CAGR of 6.8% from 2022 to 2030.

Rising Prevalence of Cardiovascular Diseases Fuel Europe Coagulation Market

Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.

A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.

Europe Coagulation Market Overview

The Europe coagulation market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe holds a significant position in the global coagulation market and is estimated to register a robust CAGR during 2022-2030. Market growth in this region is mainly attributed to the rising incidence of cardiovascular disorders, increasing advancements in medical devices, the growing aging population, and the surging awareness of coagulation analyzers.

A large number of people in Germany are suffering from cardiovascular disorders, which can be attributed to the growing aging population in the country. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million of the German population have been diagnosed with CHD till date, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, the count of deaths caused by CHD in Germany reached 147,055 (i.e., 20.98% of total deaths).

Europe Coagulation Market Revenue and Forecast to 2030 (US$ Million)

Europe Coagulation Market Segmentation

The Europe coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Europe coagulation market share in 2022.

Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Europe coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Europe coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Europe coagulation market share in 2022.

By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Europe coagulation market share in 2022.

Based on country, the Europe coagulation market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation market in 2022.

F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB are some of the leading companies operating in the Europe coagulation market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Coagulation Market - Key Industry Dynamics

• 4.1 Key Market Drivers:
  • 4.1.1 Increasing Prevalence of Blood Disorders
  • 4.1.2 Rising Prevalence of Cardiovascular Diseases
• 4.2 Market Restraints
  • 4.2.1 High Costs Associated with Coagulation Analyzers
• 4.3 Market Opportunities
  • 4.3.1 Growing Organic and Inorganic Strategies by Key Market Players
• 4.4 Future Trends
  • 4.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
• 4.5 Impact Analysis

5. Coagulation Market - Europe Market Analysis

• 5.1 Europe Coagulation Market Revenue (US$ million), 2022 - 2030

6. Europe Coagulation Market - Revenue and Forecast to 2030 - by Disease Indication

• 6.1 Overview
• 6.2 Europe Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
• 6.3 Vitamin K Deficiency
  • 6.3.1 Overview
  • 6.3.2 Vitamin K Deficiency: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Liver Disease
  • 6.4.1 Overview
  • 6.4.2 Liver Disease: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
  • 6.5.1 Overview
  • 6.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.6 Development of Circulating Anticoagulant
  • 6.6.1 Overview
  • 6.6.2 Development of Circulating Anticoagulant: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.7 Hemophilia
  • 6.7.1 Overview
  • 6.7.2 Hemophilia: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.8 Von Willebrand's Disease
  • 6.8.1 Overview
  • 6.8.2 Von Willebrand's Disease: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.9 Others
  • 6.9.1 Overview
  • 6.9.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Coagulation Market - Revenue and Forecast to 2030 - by Type

• 7.1 Overview
• 7.2 Europe Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
• 7.3 Clinical Laboratory Analyzers
  • 7.3.1 Overview
  • 7.3.2 Clinical Laboratory Analyzers: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.2.1 Europe Coagulation Market, by Clinical Laboratory Analyzers
• 7.4 Point-of-Care Testing Analyzers
  • 7.4.1 Overview
  • 7.4.2 Point-of-Care Testing Analyzers: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Coagulation Market - Revenue and Forecast to 2030 - by Offering

• 8.1 Overview
• 8.2 Europe Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
• 8.3 Diagnosis
  • 8.3.1 Overview
  • 8.3.2 Diagnosis: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.3.2.1 Europe Coagulation Market, by Diagnosis
• 8.4 Treatment
  • 8.4.1 Overview
  • 8.4.2 Treatment: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.4.2.1 Europe Coagulation Market, by Treatment

9. Europe Coagulation Market - Revenue and Forecast to 2030 - by Technology

• 9.1 Overview
• 9.2 Europe Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
• 9.3 Optical Technology
  • 9.3.1 Overview
  • 9.3.2 Optical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 Mechanical Technology
  • 9.4.1 Overview
  • 9.4.2 Mechanical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.5 Electrochemical Technology
  • 9.5.1 Overview
  • 9.5.2 Electrochemical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.6 Others
  • 9.6.1 Overview
  • 9.6.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Coagulation Market - Revenue and Forecast to 2030 - by End User

• 10.1 Overview
• 10.2 Europe Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
• 10.3 Clinical Laboratories
  • 10.3.1 Overview
  • 10.3.2 Clinical Laboratories: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 10.4 Hospitals
  • 10.4.1 Overview
  • 10.4.2 Hospitals: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 10.5 Others
  • 10.5.1 Overview
  • 10.5.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Coagulation Market - Country Analysis

• 11.1 Europe Coagulation Market, Revenue and Forecast to 2030
  • 11.1.1 Europe Coagulation Market by Country
    • 11.1.1.1 Germany
      • 11.1.1.1.1 Overview
      • 11.1.1.1.2 Germany Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.1.3 Germany Coagulation Market, by Disease Indication
      • 11.1.1.1.4 Germany Coagulation Market, by Type
      • 11.1.1.1.4.1 Germany Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.1.5 Germany Coagulation Market, by Offering
      • 11.1.1.1.5.1 Germany Coagulation Market, by Diagnosis
      • 11.1.1.1.5.2 Germany Coagulation Market, by Treatment
      • 11.1.1.1.6 Germany Coagulation Market, by Technology
      • 11.1.1.1.7 Germany Coagulation Market, by End User
    • 11.1.1.2 UK
      • 11.1.1.2.1 Overview
      • 11.1.1.2.1.1 UK Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.2.2 UK Coagulation Market, by Disease Indication
      • 11.1.1.2.3 UK Coagulation Market, by Type
      • 11.1.1.2.3.1 UK Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.2.4 UK Coagulation Market, by Offering
      • 11.1.1.2.4.1 UK Coagulation Market, by Diagnosis
      • 11.1.1.2.4.2 UK Coagulation Market, by Treatment
      • 11.1.1.2.5 UK Coagulation Market, by Technology
      • 11.1.1.2.6 UK Coagulation Market, by End User
    • 11.1.1.3 France
      • 11.1.1.3.1 Overview
      • 11.1.1.3.1.1 France Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.3.2 France Coagulation Market, by Disease Indication
      • 11.1.1.3.3 France Coagulation Market, by Type
      • 11.1.1.3.3.1 France Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.3.4 France Coagulation Market, by Offering
      • 11.1.1.3.4.1 France Coagulation Market, by Diagnosis
      • 11.1.1.3.4.2 France Coagulation Market, by Treatment
      • 11.1.1.3.5 France Coagulation Market, by Technology
      • 11.1.1.3.6 France Coagulation Market, by End User
    • 11.1.1.4 Italy
      • 11.1.1.4.1 Overview
      • 11.1.1.4.1.1 Italy Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.4.2 Italy Coagulation Market, by Disease Indication
      • 11.1.1.4.3 Italy Coagulation Market, by Type
      • 11.1.1.4.3.1 Italy Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.4.4 Italy Coagulation Market, by Offering
      • 11.1.1.4.4.1 Italy Coagulation Market, by Diagnosis
      • 11.1.1.4.4.2 Italy Coagulation Market, by Treatment
      • 11.1.1.4.5 Italy Coagulation Market, by Technology
      • 11.1.1.4.6 Italy Coagulation Market, by End User
    • 11.1.1.5 Spain
      • 11.1.1.5.1 Overview
      • 11.1.1.5.2 Spain Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.5.3 Spain Coagulation Market, by Disease Indication
      • 11.1.1.5.4 Spain Coagulation Market, by Type
      • 11.1.1.5.4.1 Spain Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.5.5 Spain Coagulation Market, by Offering
      • 11.1.1.5.5.1 Spain Coagulation Market, by Diagnosis
      • 11.1.1.5.5.2 Spain Coagulation Market, by Treatment
      • 11.1.1.5.6 Spain Coagulation Market, by Technology
      • 11.1.1.5.7 Spain Coagulation Market, by End User
    • 11.1.1.6 Rest of Europe
      • 11.1.1.6.1 Overview
      • 11.1.1.6.2 Rest of Europe Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.6.3 Rest of Europe Coagulation Market, by Disease Indication
      • 11.1.1.6.4 Rest of Europe Coagulation Market, by Type
      • 11.1.1.6.4.1 Rest of Europe Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.6.5 Rest of Europe Coagulation Market, by Offering
      • 11.1.1.6.5.1 Rest of Europe Coagulation Market, by Diagnosis
      • 11.1.1.6.5.2 Rest of Europe Coagulation Market, by Treatment
      • 11.1.1.6.6 Rest of Europe Coagulation Market, by Technology
      • 11.1.1.6.7 Rest of Europe Coagulation Market, by End User

12. Europe Coagulation Market-Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in the Coagulation Market
• 12.3 Inorganic Growth Strategies
  • 12.3.1 Overview
• 12.4 Organic Growth Strategies
  • 12.4.1 Overview

13. Company Profiles

• 13.1 Siemens Healthineers AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Nordic Biomarker AB
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 Sysmex Corp
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 F. Hoffmann-La Roche Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 Genrui Biotech Co., Ltd.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 Transasia Bio-Medicals Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 Horiba Ltd.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

• 14.1 About Us
• 14.2 Glossary of Terms